Bharat Biotech International Limited

Bharat Biotech International Limited, a biotechnology company based in Hyderabad, India, was established in 1996 by Krishna Ella. The company specializes in the production of vaccines and biotherapeutics, with a diverse range of products including vaccines for rotavirus, typhoid, and hepatitis B. In 2022, Bharat Biotech generated revenue of approximately INR 5,000 crores.

Bharat Biotech International Limited boasts a modern manufacturing facility equipped with biosafety level 3 (BSL3) laboratories. Over the years, the company has successfully manufactured more than 4 billion doses of vaccines for various diseases such as rabies, hepatitis B, typhoid, rotavirus, Japanese encephalitis, H1N1, diphtheria, tetanus, pertussis, Hib infections, polio, and chikungunya.

Furthermore, Bharat Biotech International Limited is the creator of COVAXIN®, India's first indigenous COVID-19 vaccine, which has been granted emergency use authorization by the Drugs Controller General of India (DCGI) and the World Health Organization (WHO). BBIL is also developing another COVID-19 vaccine called BBV154, which is being developed in collaboration with Precision Virologics and Washington University School of Medicine in St. Louis, Missouri.

Bharat Biotech International Limited is a research-led company that has been pursuing scientific breakthroughs and innovation for over 25 years. Furthermore, the company has also received several awards and recognitions for its contributions to biotechnology and public health.

Foundation: 1996

Headquarters: Hyderabad, Telangana
Website: https://www.bharatbiotech.com/